Kane Biotech (TSX-V:KNE) launched a consumer product test to evaluate the efficacy of its new shampoo on dermatitis and dandruff.
Research indicates that microbial biofilms may aggravate symptoms associated with dandruff and dermatitis, including eczema. Kane Biotech’s shampoo consists of its patented anti-biofilm formulation, coactiv+, and contains ingredients approved as safe for human use.
“We have anecdotal evidence that indicates our shampoo offers individuals suffering from these conditions an effective treatment option without requiring any harsh ingredients such as coal tar, ketoconazole or selenium sulfide,” Marc Edwards, Kane’s CEO, said in a statement.
“I love this type of project where we take good science and, in short order, are able to get it into the hands of consumers. The very small investment of capital associated with this consumer testing could yield substantial dividends for Kane in the future,” he added.
Kane Biotech will ship 300 samples to registered adult participants in Ontario and Manitoba with moderate-to-severe atopic dermatitis, seborrheic dermatitis and/or severe dandruff. Shipping of test samples is expected to begin in February 2020.
In a statement, long-time Kane Biotech investor, David Kemp, said, “I highly encourage those looking for a solution to dry, flaking and itching scalps to participate in Kane Biotech’s consumer product test. As sufferers of these conditions, my family and I tried this shampoo, and nothing has worked better. I’m delighted Kane is moving forward with this trial both as an investor and a consumer.”
